COINFECTION BY HEPATITIS-B VIRUS AND HEPATITIS-C VIRUS IN RENAL-TRANSPLANTATION - MORBIDITY AND MORTALITY IN 1098 PATIENTS

被引:29
作者
POUTEILNOBLE, C
TARDY, JC
CHOSSEGROS, P
MION, F
CHEVALLIER, M
GERARD, F
CHEVALLIER, P
MEGAS, F
LEFRANCOIS, N
TOURAINE, JL
机构
关键词
HEPATITIS C VIRUS; HEPATITIS B VIRUS; KIDNEY TRANSPLANTATION;
D O I
10.1093/ndt/10.supp6.122
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
The aim of the study was to analyse the influence of co-infection by hepatitis B virus (HBV) and hepatitis C virus (HCV) as compared with HCV infection alone in 1098 patients who received a kidney transplant between 1 January and 31 December 1991. At transplantation, the prevalence of anti-HCV antibodies was 21.40% (235/1098) while the prevalence of HBV infection was 9.85% (108/1096); 46 patients were co-infected with HBV and HCV, either 19.70% of HCV-infected patients and 42.60% of HBV-infected patients. Liver tests, galactose clearance and liver biopsy were compared in the 46 co-infected patients (HCV+HBV+) and in the 189 HCV-infected patients (HCV+HBV-). At the time of transplantation, cytolysis was present in 31.45% of HCV+HBV- patients (50/159) and in 40% of HCV+HBV- patients (16/40); cholestasis was present in 34.18% of HCV+HBV- patients (34/158) and 42.11% of HCV+HBV+ patients (16/38). At 6 months the incidence of biological abnormalities increased to 37% in HCV+HBV- patients (55/150) and to 52.5% in HCV+HBV+ patients (21/40), suggesting a more deleterious effect of the immunosuppressive therapy in the co-infected group. Over the course of transplantation, chronic hepatitis was present in 50% of HCV+HBV- patients and in 64.1% of HCV+HBV+ patients. Liver failure occurred in 7% of HCV+HBV- patients (12/156) and 17% of HCV+HBV+ patients (7/41). Galactose clearance was performed as a functional test in 68 patients: it was not significantly different in either group. Liver biopsy was performed in 108 patients at least once. Minimal changes were more frequent in HCV+HBV- patients while the incidence of cirrhosis was 10% in HCV+HBV- patients (8/81) and 26% in HCV+HBV+ patients (7/27). Serum HCV RNA detected by polymerase chain reaction was present in 81% of the HCV+HBV- patients (43/53) and 70% of the HCV+HBV+ patients (14/20). Patient survival rate was not significantly different in both groups at 12 years.
引用
收藏
页码:122 / 124
页数:3
相关论文
共 10 条
[1]   THE CLINICAL OUTCOME OF HEPATITIS-C VIRUS ANTIBODY-POSITIVE RENAL-ALLOGRAFT RECIPIENTS [J].
HUANG, CC ;
LIAW, YF ;
LAI, MK ;
CHU, SH ;
CHUANG, CK ;
HUANG, JY .
TRANSPLANTATION, 1992, 53 (04) :763-765
[2]   FORMULATION AND APPLICATION OF A NUMERICAL SCORING SYSTEM FOR ASSESSING HISTOLOGICAL ACTIVITY IN ASYMPTOMATIC CHRONIC ACTIVE HEPATITIS [J].
KNODELL, RG ;
ISHAK, KG ;
BLACK, WC ;
CHEN, TS ;
CRAIG, R ;
KAPLOWITZ, N ;
KIERNAN, TW ;
WOLLMAN, J .
HEPATOLOGY, 1981, 1 (05) :431-435
[3]  
KROGSGAARD K, 1993, KIDNEY INT, V43, P1353
[4]  
MORALES JM, 1993, TRANSPLANT P, V25, P1450
[5]   TRANSMISSION OF HEPATITIS-C VIRUS BY ORGAN-TRANSPLANTATION [J].
PEREIRA, BJG ;
MILFORD, EL ;
KIRKMAN, RL ;
LEVEY, AS .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 325 (07) :454-460
[6]   HEPATITIS-C VIRUS IN KIDNEY RECIPIENTS - EPIDEMIOLOGY AND IMPACT ON RENAL-TRANSPLANTATION [J].
POL, S ;
LEGENDRE, C ;
SALTIEL, C ;
CARNOT, F ;
BRECHOT, C ;
BERTHELOT, P ;
MATTLINGER, B ;
KREIS, H .
JOURNAL OF HEPATOLOGY, 1992, 15 (1-2) :202-206
[7]  
POUTEILNOBLE C, 1992, TRANSPLANT INT, V5, pS44
[8]  
POUTEILNOBLE C, 1991, TRANSPLANTATION CLIN, V13, P81
[9]   HEPATITIS C - ITS PREVALENCE IN END-STAGE RENAL-FAILURE PATIENTS AND CLINICAL COURSE AFTER KIDNEY-TRANSPLANTATION [J].
STEMPEL, CA ;
LAKE, J ;
KUO, G ;
VINCENTI, F .
TRANSPLANTATION, 1993, 55 (02) :273-276
[10]  
YNARES C, 1993, TRANSPLANT P, V25, P1466